Discover promising immuno-oncology candidates with our syngeneic platform
SynScreen PD Mode provides a comprehensive analysis of your drug's impact on the tumor's immune profile. It offers a high-throughput screening across 27 standard flow markers, 17 phenotypic markers, and 10 activation and differentiation markers, giving you a deeper understanding of the drug's immunomodulatory effects.
Fast-track your immunotherapy development with SynScreen PD Mode:
- Rapid Response Identification: Quickly pinpoint effective models and markers, saving you time and resources.
- Comprehensive Efficacy Evaluation: Assess your compound's effectiveness across well-characterized syngeneic models.
- Unveiling Drug Action: Investigate pharmacodynamic (PD) effects to understand how your drug works.
- Flexible Dosing Options: Test up to 6 daily doses to optimize your treatment plan.
- Expert Support & Reliable Data: Leverage Reaction Biology's scientific expertise and ensure robust data quality.
Study initiates on July 11th
